Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:57:32.409Z.
Calculation as of: 2026-10-06T17:57:32.409Z.
Quote observation: 2026-10-06T17:54:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8656b7a9da6ad27e4e3bee00a1f051c5b9ad9ad1f17b43070ca9e23e03b297bf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$408.21M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$403.34M
EV/EBIT Ratio
N/A
TTM Avg
5.76x
3Y Avg
28.76x
5Y Avg
28.76x
Market Cap
$424.06M
EV/EBIT Ratio
N/A
TTM Avg
16.65x
3Y Avg
16.65x
5Y Avg
16.65x
Market Cap
$411.47M
EV/EBIT Ratio
N/A
TTM Avg
135.39x
3Y Avg
60.74x
5Y Avg
42.42x
Market Cap
$412.30M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neurogene Inc. (NGNE) | $405.53M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $407.71M | N/A | N/A | N/A | N/A |
| Carlsmed, Inc. (CARL)vs › | $408.05M | N/A | N/A | N/A | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | N/A | N/A | N/A | N/A |
| Rezolute, Inc. (RZLT)vs › | $409.24M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $403.34M | N/A | 5.76x | 28.76x | 28.76x |
| Prothena Corporation plc (PRTA)vs › | $424.06M | N/A | 16.65x | 16.65x | 16.65x |
| Myriad Genetics, Inc. (MYGN)vs › | $411.47M | N/A | 135.39x | 60.74x | 42.42x |
| Strata Critical Medical, Inc. (SRTA)vs › | $412.30M | N/A | N/A | N/A | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $415.43M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
